Drug intelligence / Profile preview

ERAS-007 + osimertinib

Development stage: Unknown
Lead developer: Erasca
Modality: Small Molecules
Administration: Oral

Overview

ERAS-007 + osimertinib is a combination therapy consisting of ERAS-007, a potent and highly selective inhibitor of extracellular signal-regulated kinases (ERK 1/2), and osimertinib, an EGFR inhibitor. This combination is part of Erasca's MAPKlamp strategy, which involves combining ERAS-007 with different inhibitors targeting upstream nodes of the MAPK pathway.

Targets

MAPK3 (Mitogen-activated protein kinase 1)

Beyond the preview

Go deeper on ERAS-007 + osimertinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ERAS-007 + osimertinib.

Explore the full profile